“…Heparin binds to those same enzymes, growth factors, cytokines and viral proteins that use HSPGs as receptors [5,6,9,10], acting as a potent HSPG-antagonist. However, due to its strong anticoagulant activity, heparin cannot be used as an antiviral drug [11], prompting a series of studies aimed at identifying heparinlike molecules endowed with a more favorable therapeutic window [5,6,9,10]. To this aim, different approaches have been so far applied, including chemical modification of heparin (selective desulfation, tailoring of the saccharidic chain length, modification of the backbone flexibility), enzymatic sulfation of unsulfated glycosaminoglycans, rational design of synthetic molecules, generation of heparin nanoassemblies and screening of library of natural compounds.…”